Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most （clusters of differentiation）CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells^[1]^[2].

References:

[1]. L Franco, et al. The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes. FASEB J. 1998 Nov;12(14):1507-20. [Content Brief]

[2]. Kumi Oshima, et al. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett. 2002 May 22;519(1-3):1-7. [Content Brief]

Transmembrane Glycoprotein Related Products (367):

By Effects:	Inhibitors (229) Agonists (6) Ligands (14) Antagonists (7) Activators (10) Modulators (5)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P990607

Indatuximab	Inhibitor	98.04%
Indatuximab is a CHO-expressed chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 145.5 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-149777

B3GNT2-IN-1	Inhibitor	99.56%
B3GNT2-IN-1 is a β-1,3-N-acetylglucosaminyltransferase 2 (B3GNT2) inhibitor with an IC₅₀ of 0.009 μM. B3GNT2-IN-1 is applicable to research related to rheumatoid arthritis, ankylosing spondylitis and psoriasis.

HY-P1242

NEP(1-40)	Antagonist
NEP(1-40) is a Nogo-66 receptor (NgR) antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition.

HY-P990294

Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)	Inhibitor
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonal antibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis.

HY-P990328

Anti-AGER/RAGE Antibody (XT-M4)	Inhibitor	≥99.0%
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990260

Anti-Mouse CD86/B7-2 Antibody (GL-1)	Inhibitor	99.17%
Anti-Mouse CD86/B7-2 Antibody (GL-1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD86/B7-2. Anti-Mouse CD86/B7-2 Antibody (GL-1) can be used for the researches of inflammation and immunology, such as allergic pulmonary inflammation.

HY-P5425A

Tetanus Toxin (830–844) TFA
Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4⁺ T-cell epitope. This promiscuous CD4⁺ T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4⁺ T-cell responses in a large part of the human population).

HY-P991558

RO-5429083	Inhibitor
RO-5429083 (RG-7356) is a humanized monoclonal antibody targeting CD44. RO-5429083 binds to the extracellular domain of CD44 and inhibits constitutive EGFR phosphorylation. RO-5429083 suppresses tumor growth in xenograft models and can be used in research related to head and neck squamous cell carcinoma and acute myeloid leukemia.

HY-W016773

1,10-Decanediol		99.95%
1,10-Decanediol is a diol compound that can react with α-ketoglutarate (aKG) to generate polymeric microparticles (termed paKG MPs) for the sustained release of aKG, thereby promoting immunosuppressive regulation. Additionally, paKG MPs can bind to dendritic cells (DCs), reducing their glycolysis and mitochondrial respiration in vitro. These metabolic changes lead to the modulation of MHC-II and CD86 expression in DCs and alter the frequency of regulatory T cells (Tregs) as well as T-helper type 1/2/17 cells in vitro. 1,10-Decanediol can be used in research within the field of immunometabolism. can be used as a surfactant/stabilizer in the synthesis of nanomaterials.

HY-P991480

ONC-841	Inhibitor
ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease.

HY-P990496

Anti-PVRIG Antibody (COM701)	Inhibitor	99.14%
Anti-PVRIG Antibody (COM701) is a CHO-expressed human antibody that targets PVRIG. The predicted molecular weight (MW) of Anti-PVRIG Antibody (COM701) is 145.48 kDa. The isotype control for Anti-PVRIG Antibody (COM701) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P990361

Anti-CDCP1/CD318 Antibody (38 E11)		≥99.0%
The Anti-CDCP1/CD318 Antibody (38 E11) is a CHO-expressed human antibody targeting CDCP1/CD318. The Anti-CDCP1/CD318 Antibody (38 E11) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CDCP1/CD318 Antibody (38 E11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991068

hT84.66-M5A	Inhibitor	99.59%
hT84.66-M5A is a humanized IgG1 antibody that targets carcinoembryonic antigen (CEA). The isotype control for hT84.66-M5A can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99202

Vibostolimab	Inhibitor
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.

HY-P990061

Polzastobart	Inhibitor
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor.

HY-P5351A

Hyaluronan-binding peptide, biotin labeled TFA
Hyaluronan-binding peptide, biotin labeled TFA is a biological active peptide. (This peptide is a hyaluronan-binding peptide biotinylated through a C-terminal GGGSK linker. Hyaluronan (HA) is a nonsulfated glycosaminoglycan expressed in the extracellular matrix and on cell surfaces. HA plays a role in fertilization, embryonic development, wound healing, angiogenesis, leukocyte trafficking to inflamed tissues, and cancer metastasis. This peptide has been shown to block HA binding to CD44 receptors and inhibit T cell proliferation.).

HY-174341

CD39-IN-1	Inhibitor	99.86%
CD39-IN-1 is a selective CD39 inhibitor with an IC₅₀ value of 68.7 nM. CD39-IN-1 exerts antiproliferative effects on tumor cells and shows low toxicity to normal cell lines. CD39-IN-1 inhibits CD39-mediated eATP hydrolysis in the ATP-adenosine pathway. CD39-IN-1 is applicable for tumor-related research.

HY-128111

ASN02563583	Activator	99.21%
ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC₅₀ value of 0.64 nM in [₃₅S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases.

HY-144399

CD33 splicing modulator 1	Inhibitor	99.05%
CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease.

HY-165245

SBI-183	Inhibitor	99.8%
SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .

Name
Email *

	Sorry, but the email address you supplied was invalid.